非奈利酮对2型糖尿病合并慢性肾脏病结局的影响
FIDELIO-DKD为双盲随机对照试验,纳入5734例2型糖尿病合并CKD患者,随机接受非奈利酮或安慰剂,所有患者均已使用RAS阻断剂并调至最大耐受剂量。中位随访2.6年,非奈利酮组主要肾脏复合终点发生率为17.8%,安慰剂组为21.1%(HR 0.82;95%CI 0.73–0.93;P=0.001);关键次要心血管复合终点为13.0% vs 14.8%(HR 0.86;95%CI 0.75–0.99;P=0.03)。两组总体不良事件频率相似,但非奈利酮组高钾血症相关停药率更高(2.3% vs 0.9%)。
要点
- 纳入标准:UACR 30–<300 mg/g且eGFR 25–<60 ml/min/1.73m2并有糖尿病视网膜病变,或UACR 300–5000且eGFR 25–<75 ml/min/1.73m2。
- 所有患者随机前已将RAS阻断剂调至说明书最大耐受剂量;非奈利酮在此基础上进一步降低肾脏复合终点(HR 0.82;95%CI 0.73–0.93;P=0.001)。
- 关键次要心血管复合终点(心血管死亡、非致死性心梗、非致死性卒中、心衰住院)降低(HR 0.86;95%CI 0.75–0.99;P=0.03)。
- 高钾血症相关停药率非奈利酮组2.3%、安慰剂组0.9%,启动非奈利酮后需监测血钾。
- 总体不良事件频率两组相似。
适用人群与场景
- 2型糖尿病合并慢性肾脏病患者,已使用RAS阻断剂并调至说明书最大耐受剂量。
- 纳入条件为:UACR 30–<300 mg/g且eGFR 25–<60 ml/min/1.73m2并有糖尿病视网膜病变;或UACR 300–5000且eGFR 25–<75 ml/min/1.73m2。
诊断标准与关键阈值
- UACR以白蛋白(mg)/肌酐(g)比值计:30–<300 mg/g且eGFR 25–<60 ml/min/1.73m2并有糖尿病视网膜病变;或UACR 300–5000且eGFR 25–<75 ml/min/1.73m2。
- 主要复合终点:肾衰竭、eGFR较基线持续下降≥40%、肾脏原因死亡。
- 关键次要复合终点:心血管原因死亡、非致死性心肌梗死、非致死性卒中、心衰住院。
处置流程与药物剂量
- 第一步:确认2型糖尿病合并CKD且符合上述UACR与eGFR纳入条件。
- 第二步:将RAS阻断剂调至说明书最大耐受剂量(随机前已调整)。
- 第三步:在RAS阻断剂基础上加用非奈利酮(原文未给出具体剂量、途径和频次)。
- 监测:高钾血症相关停药率非奈利酮组2.3%、安慰剂组0.9%,需关注血钾(原文未给出具体监测阈值或处理方案)。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:双盲随机对照试验(FIDELIO-DKD,NCT02540993),由Bayer资助。
- 样本量与中心数:5734例患者,1:1随机至非奈利酮组或安慰剂组(原文未提及中心数)。
- 主要终点:中位随访2.6年,非奈利酮组504/2833例(17.8%)发生主要复合终点,安慰剂组600/2841例(21.1%)(HR 0.82;95%CI 0.73–0.93;P=0.001)。
- 关键次要终点:非奈利酮组367例(13.0%)、安慰剂组420例(14.8%)(HR 0.86;95%CI 0.75–0.99;P=0.03)。
- 不良事件:总体不良事件频率两组相似;高钾血症相关停药非奈利酮组2.3%、安慰剂组0.9%。
证据类型、等级与局限
- 证据类型:随机双盲安慰剂对照试验(RCT)。
- 局限:原文未明确列出局限;研究由药企资助;原文未提及中心数。
对床旁实践的改变
- 对符合纳入条件的2型糖尿病合并CKD患者,在RAS阻断剂最大耐受剂量基础上加用非奈利酮可降低肾脏复合终点和心血管复合终点风险。
- 启动非奈利酮后需关注高钾血症相关停药风险(非奈利酮组2.3% vs 安慰剂组0.9%)。
- 原文未提及急诊或ICU场景下的具体做法改变。
指南或共识出处
- FIDELIO-DKD试验(ClinicalTrials.gov NCT02540993),发表于N Engl J Med;由Bayer资助。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, its long-term effects on kidney and cardiovascular outcomes are unknown.
METHODS: In this double-blind trial, we randomly assigned 5734 patients with CKD and type 2 diabetes in a 1:1 ratio to receive finerenone or placebo. Eligible patients had a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 30 to less than 300, an estimated glomerular filtration rate (eGFR) of 25 to less than 60 ml per minute per 1.73 m2 of body-surface area, and diabetic retinopathy, or they had a urinary albumin-to-creatinine ratio of 300 to 5000 and an eGFR of 25 to less than 75 ml per minute per 1.73 m2. All the patients were treated with renin-angiotensin system blockade that had been adjusted before randomization to the maximum dose on the manufacturer's label that did not cause unacceptable side effects. The primary composite outcome, assessed in a time-to-event analysis, was kidney failure, a sustained decrease of at least 40% in the eGFR from baseline, or death from renal causes. The key secondary composite outcome, also assessed in a time-to-event analysis, was death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.
RESULTS: During a median follow-up of 2.6 years, a primary outcome event occurred in 504 of 2833 patients (17.8%) in the finerenone group and 600 of 2841 patients (21.1%) in the placebo group (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.93; P = 0.001). A key secondary outcome event occurred in 367 patients (13.0%) and 420 patients (14.8%) in the respective groups (hazard ratio, 0.86; 95% CI, 0.75 to 0.99; P = 0.03). Overall, the frequency of adverse events was similar in the two groups. The incidence of hyperkalemia-related discontinuation of the trial regimen was higher with finerenone than with placebo (2.3% and 0.9%, respectively).
CONCLUSIONS: In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo. (Funded by Bayer; FIDELIO-DKD ClinicalTrials.gov number, NCT02540993.).
参考来源
- Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020. PMID: 33264825. doi:10.1056/NEJMoa2025845
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。